Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE-Reference-Cited by-同舟云学术

Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE

Published:2015-08 Issue:4 Volume:8 Page:273-278
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Divella Rosa^ORCID,Daniele Antonella,Abbate Ines,Savino Eufemia,Casamassima Porzia,Sciortino Giancarlo,Simone Giovanni,Gadaleta-Caldarola Gennaro,Fazio Vito,Gadaleta Cosimo Damiano,Sabbà Carlo,Mazzocca Antonio

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature;Abdel-Rahman;Dig Dis Sci,2013

2. A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma;Wang;Can J Gastroenterol,2013

3. Serpins for diagnosis and therapy in cancer;Zheng;Cardiovasc Hematol Disord Drug Targets,2013

4. Biochemical properties of plasminogen activator inhibitor-1;Dupont;Front Biosci (Landmark Ed),2009

5. Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1);Lademann;Thromb Haemost,2008

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Constructing a prognostic model for hepatocellular carcinoma based on bioinformatics analysis of inflammation-related genes;Frontiers in Medicine;2024-07-11

2. Nomogram built based on machine learning to predict recurrence in early-stage hepatocellular carcinoma patients treated with ablation;Frontiers in Oncology;2024-05-10

3. SERPINE-1 gene polymorphism in patients with cardiovascular diseases;Kazan medical journal;2024-04-01

4. Network Pharmacology Combined with Experimental Validation Reveals the Anti-tumor Effect of Duchesnea indica against Hepatocellular Carcinoma;Journal of Cancer;2023

5. A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE;Journal of Oncology;2022-09-28